Review Article
New Progress of Epigenetic Biomarkers in Urological Cancer
Table 1
Overview of bladder cancer biomarkers.
| | Biomarker | Sample | Type | Diagnosis, treatment, or prognosis |
| | Bladder cancer |
| | RUNX3 | Tissue | DNA methylation | Diagnosis | | RSPH9 | Urine | DNA methylation | Diagnosis, prognosis | | PCDH10, PCDH17 | Urine | DNA hypermethylation | Treatment, prognosis | | PCDH17, POU4F2 | Urine | DNA methylation | All | | TWIST1, NID2 | Urine | DNA methylation | Diagnosis | | CDH1, CDH13, RASSF1A, APC | Urine | DNA methylation | Prognosis | | RASSF1A, CDH1, TNFSR25, EDNRB, APC | Urine | DNA methylation | Prognosis | | H4K20 | Tissue | Histone modification | Prognosis | | KLF4 | Urine | Histone modification | Treatment | | H4K20me3 | Tissue | Expression level | Prognosis | miR-422a-3p
miR-486-3p
miR-103a-3p
miR-27a-3p | Tissue (serum) | Overexpression | Prognosis | | miRNA-146a-5p | Urine | Overexpression | Prognosis | | miRNA-145 | Urine | Overexpression | Prognosis |
|
|
